Request Demo
Last update 14 May 2026
DS-2325a
Last update 14 May 2026
Overview
Basic Info
Drug Type Gene therapy |
Synonyms a fusion protein comprised of genetically engineered human serine peptidase inhibitor KAZAL Type 2 (SPINK2) and human immunoglobulin G (IgG) 1 Fc., DS 2325A, DS-2325A + [1] |
Target |
Action inhibitors |
Mechanism KLK5 inhibitors(kallikrein related peptidase 5 inhibitors), Gene transference(Gene transference) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Login to view timeline
Related
3
Clinical Trials associated with DS-2325aNCT05979831
A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
NCT05583669
A Phase 1, Subject- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
NCT05388903
A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
100 Clinical Results associated with DS-2325a
Login to view more data
100 Translational Medicine associated with DS-2325a
Login to view more data
100 Patents (Medical) associated with DS-2325a
Login to view more data
100 Deals associated with DS-2325a
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Netherton Syndrome | Phase 2 | France | 28 Sep 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 9 | (DS-2325a (Observational Part)) | worwlrblhl = lbebzybzyt lxebxokguh (njfuvbvvoq, wukdrnsomd - uqvdmnkvpl) View more | - | 14 May 2026 | ||
Placebo (Placebo (Observational Part)) | worwlrblhl = eomuhvwajt lxebxokguh (njfuvbvvoq, uhwhfuvdxp - wsihuxuxeg) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free